Advertisement

Topics

$200K Saved With First-Line Docetaxel for Prostate Cancer

03:42 EDT 12 Jun 2018 | Medscape

For the first time, there is a cost-effectiveness study on two systemic drugs used in the treatment of newly diagnosed metastatic prostate cancer.
Medscape Medical News

Original Article: $200K Saved With First-Line Docetaxel for Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "$200K Saved With First-Line Docetaxel for Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement